Jodie Pope Morrison Sells 9,896 Shares of Q32 Bio (NASDAQ:QTTB) Stock

Q32 Bio Inc. (NASDAQ:QTTB) CEO Jodie Pope Morrison sold 9,896 shares of Q32 Bio stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $4.51, for a total value of $44,630.96. Following the completion of the transaction, the chief executive officer owned 89,104 shares in the company, valued at $401,859.04. The trade was a 10.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jodie Pope Morrison also recently made the following trade(s):

• On Tuesday, December 2nd, Jodie Pope Morrison sold 22,506 shares of Q32 Bio stock. The stock was sold at an average price of $3.46, for a total value of $77,870.76.

Q32 Bio Stock Down 4.2%

Shares of NASDAQ QTTB opened at $4.56 on Friday. Q32 Bio Inc. has a 12 month low of $1.35 and a 12 month high of $6.37. The company has a market cap of $56.09 million, a price-to-earnings ratio of -1.33 and a beta of 0.16. The business has a fifty day simple moving average of $3.81 and a 200-day simple moving average of $2.90.

Key Headlines Impacting Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Institutional Investors Weigh In On Q32 Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP purchased a new position in shares of Q32 Bio during the 2nd quarter valued at $25,000. Acadian Asset Management LLC purchased a new stake in shares of Q32 Bio during the first quarter worth $50,000. Two Sigma Investments LP acquired a new stake in Q32 Bio during the third quarter valued at $62,000. ADAR1 Capital Management LLC purchased a new position in Q32 Bio in the fourth quarter valued at about $66,000. Finally, AQR Capital Management LLC purchased a new position in Q32 Bio in the first quarter valued at about $68,000. Hedge funds and other institutional investors own 31.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on QTTB. HC Wainwright began coverage on shares of Q32 Bio in a research report on Wednesday. They issued a “buy” rating and a $13.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $14.00.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.